gained Tuesday after the Israeli-based company said U.S. regulators have approved its generic version of
successful antibiotic Augmentin.
Teva said the treatment, approved by the Food and Drug Administration, combines amoxicillin and clavulanate potassium in creating a broad spectrum antibiotic.
The company has yet to set a launch date.
Though Israeli-based, about 90% of Teva's sales are in North America and Europe.
Teva shares rose $1.38, or 2.1%, to $66.87.
As originally published, this story contained an error. Please see
Corrections and Clarifications.